M
Mark Krailo
Researcher at University of Southern California
Publications - 425
Citations - 25624
Mark Krailo is an academic researcher from University of Southern California. The author has contributed to research in topics: Sarcoma & Cancer. The author has an hindex of 85, co-authored 394 publications receiving 22772 citations. Previous affiliations of Mark Krailo include Food and Drug Administration & Rutgers University.
Papers
More filters
Journal ArticleDOI
Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.
Holcombe E. Grier,Mark Krailo,Nancy J. Tarbell,Michael P. Link,Chris Fryer,Douglas J. Pritchard,Mark C. Gebhardt,Paul S. Dickman,Elizabeth J. Perlman,Paul A. Meyers,Sarah S. Donaldson,Sheila Moore,Aaron R. Rausen,Teresa J. Vietti,James S. Miser +14 more
TL;DR: The addition of ifosfamide and etoposide to a standard regimen does not affect the outcome for patients with metastatic disease, but it significantly improves the outcomeFor patients with nonmetastatic Ewing's Sarcoma, primitive neuroectodermal tumor of bone, or primitive sarcoma of bone.
Journal ArticleDOI
‘Hormonal’ risk factors, ‘breast tissue age’ and the age-incidence of breast cancer
TL;DR: A quantitative description of ‘breast tissue age’ is suggested which brings the age–incidence curve of breast cancer into line with the common log–log cancers and explains quantitatively the known key risk factors.
Journal ArticleDOI
Osteosarcoma: A Randomized, Prospective Trial of the Addition of Ifosfamide and/or Muramyl Tripeptide to Cisplatin, Doxorubicin, and High-Dose Methotrexate
Paul A. Meyers,Cindy L. Schwartz,Mark Krailo,Eugenie S. Kleinerman,Donna L. Betcher,Mark L. Bernstein,Ernest U. Conrad,William S. Ferguson,Mark C. Gebhardt,Allen M. Goorin,Michael E. Harris,John H. Healey,Andrew G. Huvos,Michael P. Link,Joseph Montebello,Helen Nadel,Michael Nieder,Judith K. Sato,Gene P. Siegal,Michael Weiner,Robert J. Wells,Lester E. Wold,Richard B. Womer,Holcombe E. Grier +23 more
TL;DR: The addition of MTP to chemotherapy might improve EFS, but additional clinical and laboratory investigation will be necessary to explain the interaction between ifosfamide and MTP.
Journal ArticleDOI
Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group
Paul A. Meyers,Cindy L. Schwartz,Mark Krailo,John H. Healey,Mark L. Bernstein,Donna L. Betcher,William S. Ferguson,Mark C. Gebhardt,Allen M. Goorin,Michael E. Harris,Eugenie S. Kleinerman,Michael P. Link,Helen Nadel,Michael Nieder,Gene P. Siegal,Michael A. Weiner,Robert J. Wells,Richard B. Womer,Holcombe E. Grier +18 more
TL;DR: The addition of ifosfamide to cisplatin, doxorubicin, and methotrexate did not enhance EFS or overall survival for patients with osteosarcoma, and the addition of MTP to chemotherapy resulted in a statistically significant improvement in overall survival and a trend toward better EFS.
Journal ArticleDOI
Randomized Controlled Trial of Interval-Compressed Chemotherapy for the Treatment of Localized Ewing Sarcoma: A Report From the Children's Oncology Group
Richard B. Womer,Daniel C. West,Mark Krailo,Paul S. Dickman,Bruce R. Pawel,Holcombe E. Grier,Karen J. Marcus,Scott L. Sailer,John H. Healey,John P. Dormans,Aaron R. Weiss +10 more
TL;DR: For localized Ewing sarcoma, chemotherapyadministered every 2 weeks is more effective than chemotherapy administered every 3 weeks, with no increase in toxicity.